While Avalo Therapeutics Inc has overperformed by 2.07%, investors are advised to look at stock chart patterns for technical insight. Within its last year performance, AVTX fell by -33.51%, with highs and lows ranging from $16.00 to $3.39, whereas the simple moving average fell by -36.28% in the last 200 days.
On June 02, 2025, H.C. Wainwright started tracking Avalo Therapeutics Inc (NASDAQ: AVTX) recommending Buy. A report published by Stifel on March 25, 2025, Initiated its previous ‘Buy’ rating for AVTX. Jefferies also rated AVTX shares as ‘Buy’, setting a target price of $23 on the company’s shares in an initiating report dated March 25, 2025. Piper Sandler Initiated an Overweight rating on February 28, 2025, and assigned a price target of $48. Wedbush initiated its ‘Outperform’ rating for AVTX, as published in its report on February 21, 2025. BTIG Research’s report from December 19, 2024 suggests a price prediction of $40 for AVTX shares, giving the stock a ‘Buy’ rating. H.C. Wainwright also rated the stock as ‘Neutral’.
Analysis of Avalo Therapeutics Inc (AVTX)
In order to gain a clear picture of Avalo Therapeutics Inc’s future performance, a variety of well-rounded analysis and research techniques can be applied, with equity being the most critical. The goal here is to ensure that your current return on equity of 678.24% is sufficient for you to turn a profit off your investment. Taking into account the quick ratio of the company, currently set at 22.61, you can see that the company can cover any debts it may have, which can easily be seen in the annual report of the company.
An average volume of 74.93K can be a very valuable indicator of volatility for AVTX stock. On a monthly basis, the volatility of the stock is set at 7.57%, whereas on a weekly basis, it is put at 5.79%, with a gain of 3.13% over the past seven days. Furthermore, long-term investors anticipate a median target price of $29.88, showing growth from the present price of $4.94, which can serve as yet another indication of whether AVTX is worth investing in or should be passed over.
How Do You Analyze Avalo Therapeutics Inc Shares?
In addition to the fundamentals, you should also consider how many employees own shares in the company. This is because the values should be in line with investors’ expectations. As such, the current holdings of company stock inside the company are set at 20.47%. This can enable you to see the extent to which executives own the company’s stock. As opposed to executive stock, institutional ownership accounts for 62.85% of the company’s shares, contributing to an indication of company value, since large shareholders may signify strength within the organization.
AVTX shares are owned by institutional investors to the tune of 62.85% at present.
